{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:35:49Z","timestamp":1780392949225,"version":"3.54.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Glioblastoma (GBM) is the most common primary malignant tumor of the brain with high morbidity and mortality without an effective therapeutic option currently. This study aimed to evaluate the feasibility and safety of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu] Lu-prostate-specific membrane antigen (PSMA) therapy in patients with progressive\/persistent refractory glioblastoma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>\n                      This is a prospective single-arm pilot clinical trial with inclusion of 10 patients with progressive\/persistent GBM on standard of care therapy. After evaluation of eligibility by [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc] Tc-PSMA single-photon emission computed tomography (SPECT)\/ low-dose CT, the patients received 2\u20136 cycles of 100\u2013150 mCi with 4\u20135 weeks interval, and toxicity was assessed with regular hematologic and renal function tests as well as clinical history and examination. The response to therapy was also evaluated with magnetic resonance imaging (MRI).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 23 patients who were referred for this trial, 10 patients finally were included and received 3\u20136 cycles [\n                      <jats:sup>177<\/jats:sup>\n                      Lu] Lu-PSMA therapy. No hematologic or renal toxicity was noted. Clinical improvement or stability was seen in 9\/10 patients. The comparison of MRI before and after therapy revealed 3 patients with partial response, 4 patients with stable disease and 3 patients with progressive disease. Six-month and 1-year survival rates were 100% and 80% after first dose of [\n                      <jats:sup>177<\/jats:sup>\n                      Lu] Lu-PSMA therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      This study demonstrated that [\n                      <jats:sup>177<\/jats:sup>\n                      Lu] Lu-PSMA therapy could be a safe and potentially effective salvage therapy in the progressive\/persistent GBM and should be more evaluated with further dedicated study to assess more precise selection criteria and therapeutic protocol and timing.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006219","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:00:44Z","timestamp":1768579244000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Safety and Feasibility of [177Lu] Lu-PSMA Therapy in Glioblastoma"],"prefix":"10.1097","author":[{"given":"Tahereh","family":"Ghaedian","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Namazi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5265-3882","authenticated-orcid":false,"given":"Abdolmajid","family":"Alipour","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Namazi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Rakhsha","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7423-3312","authenticated-orcid":false,"given":"Hamid","family":"Nasrollahi","sequence":"additional","affiliation":[{"name":"Department of Radio-oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrnaz","family":"Ghaedian","sequence":"additional","affiliation":[{"name":"Department of Radiology, School of Medicine, ShirazUniversity of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Yazdani","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Namazi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4595-1928","authenticated-orcid":false,"given":"Mohammad","family":"Atefi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Namazi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Shabani","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Namazi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8901-852X","authenticated-orcid":false,"given":"Nahid","family":"Masoudi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Namazi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"R1-20260216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14791\/btrt.2017.5.1.1","article-title":"Bevacizumab in recurrent glioma: patterns of treatment failure and implications","volume":"5","author":"Li","year":"2017","journal-title":"Brain Tumor Res Treat"},{"key":"R2-20260216","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.1999.17.8.2572","article-title":"Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials","volume":"17","author":"Wong","year":"1999","journal-title":"J Clin Oncol"},{"key":"R3-20260216","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3892\/mco.2023.2669","article-title":"Comparison of the outcomes following bevacizumab and\/or temozolamide\/radiosurgery treatment in patients with glioblastoma","volume":"19","author":"Aravantinou-Fatorou","year":"2023","journal-title":"Mol Clin Oncol"},{"key":"R5-20260216","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrn2175","article-title":"Angiogenesis in brain tumours","volume":"8","author":"Jain","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"R6-20260216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-14-26","article-title":"Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases","volume":"14","author":"Nomura","year":"2014","journal-title":"Cancer Cell Int"},{"key":"R7-20260216","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1097\/RLU.0000000000001769","article-title":"Prostate-specific membrane antigen\u2013targeted imaging with [18F] DCFPyL in high-grade gliomas","volume":"42","author":"Fragomeni","year":"2017","journal-title":"Clin Nucl Med"},{"key":"R8-20260216","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00259-020-04715-z","article-title":"Tumor uptake in glioblastoma multiforme after IV injection of [177 Lu] Lu-PSMA-617","volume":"47","author":"Kunikowska","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R9-20260216","first-page":"1097","article-title":"Early impact of bevacizumab on the 99mTc-HYNIC-PSMA-11 uptake in a case of recurrent glioblastoma multiforme","volume":"10","author":"Ghaedian","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R10-20260216","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.5858\/arpa.2010-0740-OA","article-title":"Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme","volume":"135","author":"Wernicke","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"R11-20260216","doi-asserted-by":"crossref","first-page":"646387","DOI":"10.3389\/fonc.2021.646387","article-title":"PSMA expression in glioblastoma as a basis for theranostic approaches: a retrospective, correlational panel study including immunohistochemistry, clinical parameters and PET imaging","volume":"11","author":"Holzgreve","year":"2021","journal-title":"Front Oncol"},{"key":"R12-20260216","doi-asserted-by":"crossref","first-page":"5358545","DOI":"10.1155\/2022\/5358545","article-title":"Prostate-specific membrane antigen as target for neuroimaging of central nervous system tumors","volume":"2022","author":"Stopa","year":"2022","journal-title":"Mol Imaging"},{"key":"R13-20260216","first-page":"927","article-title":"Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients","volume":"7","author":"JS","year":"1987","journal-title":"Anticancer Res"},{"key":"R14-20260216","first-page":"2674","article-title":"Prostate-specific membrane antigen is produced in tumor-associated neovasculature","volume":"5","author":"Chang","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R15-20260216","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2559.2007.02635.x","article-title":"Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique","volume":"50","author":"Mhawech-Fauceglia","year":"2007","journal-title":"Histopathology"},{"key":"R16-20260216","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.3390\/jcm11216590","article-title":"PSMA expression in solid tumors beyond the prostate gland: ready for theranostic applications?","volume":"11","author":"Lauri","year":"2022","journal-title":"J Clin Med"},{"key":"R17-20260216","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.21873\/anticanres.17037","article-title":"Systematic review of the first 40 cases of 177Lu-PSMA therapy in the treatment of non-prostatic cancer","volume":"44","author":"Golan","year":"2024","journal-title":"Anticancer Res"},{"key":"R18-20260216","doi-asserted-by":"crossref","first-page":"1165694","DOI":"10.3389\/fonc.2023.1165694","article-title":"The efficacy of 99mTc-HYNIC-PSMA SPECT\/CT in detecting primary lesions and metastasis in newly diagnosed prostate cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"R19-20260216","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3390\/pharmaceutics14050996","article-title":"[99mTc] Tc-labeled plectin-targeting peptide as a novel SPECT probe for tumor imaging","volume":"14","author":"Gong","year":"2022","journal-title":"Pharmaceutics"},{"key":"R20-20260216","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.nucmedbio.2017.01.010","article-title":"99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen","volume":"48","author":"Xu","year":"2017","journal-title":"Nucl Med Biol"},{"key":"R21-20260216","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/RLU.0000000000005365","article-title":"Prostate-specific membrane antigen use in glioma management: past, present, and future","volume":"49","author":"McBriar","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R22-20260216","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1097\/RLU.0000000000004903","article-title":"68Ga-PSMA-11 PET\/CT imaging in brain gliomas and its correlation with clinicopathological prognostic parameters","volume":"48","author":"Verma","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R23-20260216","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40336-024-00678-5","article-title":"Pre-operative differentiation of glioma grades using [99mTc] Tc-HYNIC-PSMA-11 SPECT\/CT: a preliminary study","volume":"13","author":"Ghaedian","year":"2025","journal-title":"Clin Transl Imaging"},{"key":"R24-20260216","first-page":"1097","article-title":"Excellent response of glioblastoma multiforme to [177Lu] Lu-PSMA therapy","volume":"10","author":"Ghaedian","year":"2022","journal-title":"Clin Nucl Med"},{"key":"R25-20260216","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1097\/RLU.0000000000003142","article-title":"177Lu-\/68Ga-PSMA theranostics in recurrent glioblastoma multiforme: proof of concept","volume":"45","author":"Kumar","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R26-20260216","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1097\/RLU.0000000000004612","article-title":"Short-interval, low-dose [177Lu] Lu\u2013prostate-specific membrane antigen in the treatment of refractory glioblastoma","volume":"48","author":"More","year":"2023","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T02:00:11Z","timestamp":1771207211000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006219","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"2025-07-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}